Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation

AAPS J. 2009 Mar;11(1):39-44. doi: 10.1208/s12248-008-9075-y. Epub 2009 Jan 29.


The endogenous cannabinoid N-arachidonoyl ethanolamine (anandamide; AEA) produces most of its pharmacological effects by binding and activating CB(1) and CB(2) cannabinoid receptors within the CNS and periphery. However, the actions of AEA are short lived because of its rapid catabolism by fatty acid amide hydrolase (FAAH). Indeed, FAAH knockout mice as well as animals treated with FAAH inhibitors are severely impaired in their ability to hydrolyze AEA as well as a variety of noncannabinoid lipid signaling molecules and consequently possess greatly elevated levels of these endogenous ligands. In this mini review, we describe recent research that has investigated the functional consequences of inhibiting this enzyme in a wide range of animal models of inflammatory and neuropathic pain states. FAAH-compromised animals reliably display antinociceptive and anti-inflammatory phenotypes with a similar efficacy as direct-acting cannabinoid receptor agonists, such as Delta(9)-tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis sativa. Importantly, FAAH blockade does not elicit any apparent psychomimetic effects associated with THC or produce reinforcing effects that are predictive of human drug abuse. The beneficial effects caused by FAAH blockade in these models are predominantly mediated through the activation of CB(1) and/or CB(2) receptors, though noncannabinoid mechanisms of actions can also play contributory or even primary roles. Collectively, the current body of scientific literature suggests that activating the endogenous cannabinoid system by targeting FAAH is a promising strategy to treat pain and inflammation but lacks untoward side effects typically associated with Cannabis sativa.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Amidohydrolases / antagonists & inhibitors*
  • Amidohydrolases / deficiency
  • Amidohydrolases / genetics
  • Amidohydrolases / physiology
  • Analgesics / pharmacology*
  • Analgesics / toxicity
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Anti-Inflammatory Agents, Non-Steroidal / toxicity
  • Arachidonic Acids / metabolism*
  • Disease Models, Animal
  • Dronabinol / pharmacology
  • Dronabinol / toxicity
  • Drug Delivery Systems
  • Drug Evaluation, Preclinical
  • Endocannabinoids
  • Glycerides / metabolism
  • Humans
  • Inflammation / chemically induced
  • Inflammation / drug therapy*
  • Inflammation / physiopathology
  • Mice
  • Mice, Knockout
  • Pain / drug therapy*
  • Pain / physiopathology
  • Peroxisome Proliferator-Activated Receptors / drug effects
  • Peroxisome Proliferator-Activated Receptors / physiology
  • Polyunsaturated Alkamides / metabolism*
  • Rats
  • Receptors, Cannabinoid / drug effects
  • Receptors, Cannabinoid / metabolism
  • Receptors, Opioid / drug effects
  • Receptors, Opioid / physiology
  • TRPV Cation Channels / drug effects
  • TRPV Cation Channels / physiology


  • Analgesics
  • Anti-Inflammatory Agents, Non-Steroidal
  • Arachidonic Acids
  • Endocannabinoids
  • Glycerides
  • Peroxisome Proliferator-Activated Receptors
  • Polyunsaturated Alkamides
  • Receptors, Cannabinoid
  • Receptors, Opioid
  • TRPV Cation Channels
  • TRPV1 receptor
  • Dronabinol
  • glyceryl 2-arachidonate
  • Amidohydrolases
  • fatty-acid amide hydrolase
  • anandamide